Press

A freemium, evidence-graded community, research library, and care toolkit for perimenopause and menopause. Founded by a Victoria-based communications professional and cancer survivor who was pushed into menopause chemically and then surgically, and found almost no map for any of it.

British Columbia began offering free public coverage of hormone replacement therapy in March 2026. Western Canada's first Complex Menopause Clinic opened at BC Women's Hospital in 2025. The FDA removed its black-box warning for systemic estrogen in November 2025. Globally, an estimated 1.2 billion women will be in or past menopause by 2030, roughly one in seven people on the planet. The average time from a woman's first perimenopause symptom to diagnosis is still 4.6 years (Newson Health). Nila is built to close that gap.

The investment picture hasn't caught up. Roughly 6% of private healthcare investment goes to women's health, even after a record US$2.6B year in 2024 (SVB, 2025). Between 2019 and 2023, companies working on erectile dysfunction raised US$1.24B while endometriosis, a condition affecting an estimated 190 million people with a 7-to-10-year diagnostic delay, drew just US$44M (npj Women's Health, 2024). Less than 1% of healthcare funding in that window went to women-specific conditions (McKinsey Health Institute, 2025). Women weren't required in US clinical trials until 1993.

The FemTech market is projected to grow from US$39B (2024) to US$97B (2030); the untapped menopause-medication market alone is estimated at US$120–230B annually. McKinsey and the WEF put the prize for closing the broader women's-health gap at US$1T in GDP and roughly 137 million more women in full-time work by 2040, about $3 returned for every $1 invested. A 2026 analysis from the World Economic Forum, Kearney Health Institute, the Gates Foundation, and Wellcome Leap specifically identified menopause as under-resourced relative to its disease burden.

In Canada, unmanaged menopause symptoms cost the Canadian economy an estimated $3.5 billion a year: $3.3 billion in lost income borne by women themselves (reduced hours, reduced pay, or leaving the workforce) and $237 million in lost employer productivity, roughly 540,000 lost workdays.

Sources: SVB Innovation in Women's Health (2025); npj Women's Health (2024); McKinsey Health Institute (2025); Grand View Research FemTech market; WEF/Kearney/Gates/Wellcome Leap (2026); Menopause Foundation of Canada, Menopause and Work in Canada (Deloitte / Leger, October 2023).

• A full platform. The chat, community, research library, symptom guides, and a private daily check-in are equally central parts of the product.
• Guides for loved ones. Five free guides for a partner, her kids (teens or grown), her closest friend, the adult child of a postmenopausal mother, and a couples-conversation guide with six scripted openings. No competitor product addresses the support network directly.
• Built for whom the research left out. Twenty named pathways include neurodivergent women (the ADHD/autism–perimenopause connection), post-cancer menopause, Black women (whose vasomotor symptoms last a median of 10.1 years vs. 7.4 overall), trans and non-binary hormone journeys, and sole carers, plus a standalone research-gaps page naming where the evidence is thinnest, with sources. The full breakdown lives at hellonila.com/who-this-is-for: one door, no single-axis choice required.
• Evidence-graded and dated. Every research card carries an Evidence A/B/C strength tag and a region tag (Global, Canada, US, UK, or Personal for lived-experience essays). The library is updated roughly every quarter, with no affiliate links and no paid placement.
• Doctor-ready by design. A clinician-questions worksheet compiles selections from across the site into a printable appointment summary; Premium adds a one-page health record pulling together check-in trends, supplements, and profile.

Lane-by-lane comparison: hellonila.com/why-nila

Nila launched May 21, 2026. In the roughly 60 days since, hellonila.com has drawn about 4,100 visitors and 19,500 pageviews, with daily traffic climbing from around 25 visits at launch to a sustained 50–85 a day through June and July, and single days already topping 119.

The community has grown to 119 members (a third of them in the past 30 days), posting 44 threads and 78 comments. Members have opened 92 chat sessions with Nila's AI companion, exchanging more than 500 messages, alongside symptom logs, weekly check-ins, and saved items in personal stacks. The newsletter, launched July 4, already has 602 subscribers.

Behind it: 431 research articles, built and edited by a single founder in under three months; seven verified practitioners now listed in the directory; and a partnership inquiry underway. The iOS app carries a 5-star rating from its early reviewers; the Android app is in closed testing. For a solo-built health platform in its first 60 days, these numbers reflect both meaningful engagement and genuine unmet need.

For immediate release · Women's health · Digital health · Femtech · Victoria, BC · July 15, 2026

An evidence-graded, community-powered menopause platform built by a survivor. Now on web and iOS; Android in closed testing.

Media timing note: Android is in closed testing. Production review unlocks once Play Console requirements are met. Interview slots with founder Erin Beattie are limited.

What Nila is

Why now

Built for whom the research left out

Nila organizes its content into 20 named pathways based on how menopause actually arrives in someone's life, with several built for groups underrepresented in both research and the mainstream conversation. Vasomotor symptoms last a median of 10.1 years for Black women, versus 7.4 years overall, and much of the landmark research hasn't reflected that. One in three women reaches menopause during or after cancer treatment. Estrogen quietly regulates dopamine, focus, and sensory filtering, so women managing ADHD or autism can find that strategies that worked for decades suddenly stop working. Nila has dedicated pathways for each, plus trans and non-binary hormone journeys, sole carers, and shifts in identity and mood, along with a standalone research-gaps page that names, with sources, where the evidence base is thinnest. The full list of who Nila is written for is laid out at hellonila.com/who-this-is-for.

What's in it

The research library holds 17 curated shelves and 77 symptom guides across seven body systems, each graded for evidence quality and dated. The treatments section spans six clinical areas, with in-depth explainers on the WHI study, cancer-risk concepts, and body-identical versus bioidentical hormones. A 110-entry relief finder and a verified practitioner directory (filterable by modality, region, and lived-experience affirmation) round out the toolkit. Nila (hellonila.com) launched on May 21, 2026; its iOS app followed on June 30, and the Android app is now in closed testing. Membership is freemium: the community, guides, and daily check-in are free to join, with a paid Premium tier for individuals and paid seats for employers.

Two months in, by the numbers

Five promises, written down

1. 01. No data is ever sold: not now, not anonymized, not if the company is acquired.
2. 02. Sources are cited and dated, with evidence grades updated as research changes.
3. 03. Sponsorships are disclosed inline, never in fine print.
4. 04. Counselling, treatment, identity, and crisis pages carry no sponsorship, ever.
5. 05. Pro-information: editorially independent of any treatment agenda.

For employers

About Nila (backgrounder)

Nila is a freemium community, evidence-graded research library, and care toolkit for perimenopause and menopause (naturally, surgically, or medically induced), founded in Victoria, BC. The community, guides, and daily check-in are free to join. Premium unlocks the full research library, daily symptom tracking with doctor-ready exports, structured programmes, and members-only community rooms for CAD $12.99/month or $129/year; employers can buy Premium seats for staff through Nila for Teams. Nila is a member of Femtech Canada and The Menopause Society, and is listed in the FemTech Observatory 2026.

###

Erin Beattie is the editor, researcher, developer, founder, and funder behind Nila. Her path to building it began eighteen years earlier, with undiagnosed endometriosis. In September 2023, she was diagnosed with hormone-positive breast cancer. Treatment, including Tamoxifen and Zoladex, deliberately suppressed her estrogen, inducing chemical menopause. A hysterectomy prompted by MSH2 gene flags (a marker for Lynch syndrome) followed; that surgery is where her endometriosis was finally confirmed, and it triggered full acute surgical menopause. Because her cancer is hormone-positive, systemic HRT remains a genuinely open question for her; she currently uses local vaginal estrogen, with research on further options still evolving. That gray zone, neither cleared for hormone therapy nor ruled out from it, is central to why Nila is built for more than one kind of menopause story.

"Most of what's out there treats menopause as one story. Nila is built for the version that arrived after surgery, after cancer, alongside ADHD, or outside the timeline anyone prepared you for."

Photo · Bio · hellonila.com/about

Nila enters a category that is finally being priced honestly. Roughly 6% of private healthcare investment goes to women's health, against a FemTech market projected to grow from US$39B in 2024 to US$97B by 2030. The untapped menopause-medication market alone is estimated at US$120–230B/year. 450 million women are currently in or past menopause; 1.2 billion will be by 2030. Women weren't required in US clinical trials until 1993, so most legacy evidence was built on male bodies. McKinsey estimates closing the women's-health gap is a US$1T+ GDP opportunity by 2040.

Virtual menopause clinics (US$99–$379/month, regional, prescription-bound) have validated the category. Nila owns the bigger half: moderated community, evidence-based research library, symptom and treatment guides, and a private companion at CAD $12.99/month, globally, for the populations clinics structurally don't serve (induced menopause, post-cancer, neurodivergent, trans and non-binary, women of colour, sole carers).

Sources: SVB Innovation in Women's Health 2025; Grand View Research FemTech market; NIH ORWH; McKinsey Health Institute / WEF, Closing the Women's Health Gap (2024).